NovaStem (NOVASTEM), recognized by Forbes Korea as one of Korea’s innovative technologies, demonstrates its technological excellence on the global stage.
Calm Laser, a new regenerative laser platform, unveiled for the first time, highlighting synergistic applications with autologous cell concentrates.
As the only Korean company holding both Japan PMDA and China NMPA Class III Medical Device approvals, REV-MED continues to set new global standards in regenerative medicine.
Global regenerative medicine company REV-MED Co., Ltd. (CEO: Edward BG Shin) participated in WHX Dubai 2026 (formerly Arab Health), the largest healthcare exhibition in the Middle East and North Africa (MENA) region, held from February 9–12, 2026 at the Dubai Exhibition Centre, showcasing Korea’s advanced regenerative medicine technologies to an international audience.
At the exhibition, REV-MED prominently featured its flagship platform, NovaStem (NOVASTEM), which was recently recognized by Forbes Korea as an innovative technology product. Built on proprietary autologous biologics separation and concentration technology, NovaStem has attracted significant attention from healthcare professionals worldwide for transforming the uncertainty of regenerative therapies into a more standardized and reliable process.
Global buyers visiting the REV-MED booth expressed strong interest in NovaStem’s precise cell concentration technology and user-friendly workflow. The platform’s technological sophistication, validated through industry recognition, has served as a key driver in discussions with potential international partners.
Introducing Calm Laser: A New Regenerative Medicine Platform
REV-MED also unveiled its latest innovation, Calm Laser, a micro-pulse ND:YAG laser system, presenting a new direction for regenerative medicine applications.
Calm Laser is designed to deliver energy deep into the dermis while minimizing epidermal damage, helping stimulate dormant cellular activity and supporting tissue regeneration.
The company highlighted a next-generation treatment concept that combines:
- Calm Laser for cellular activation
- NovaStem autologous cell concentrates for regenerative signaling support
This integrated regenerative approach received positive feedback from healthcare professionals and industry stakeholders attending the exhibition.
Comprehensive Product Portfolio
In addition to NovaStem and Calm Laser, REV-MED showcased several key technologies, including:
- ReWave – UHFOM (Ultra High Frequency Oscillation Microwave) beauty device
- Hilthera 4.0 – Advanced high-power laser platform
Together, these products demonstrate REV-MED’s commitment to providing a comprehensive regenerative and aesthetic technology portfolio.
Global Regulatory Leadership
REV-MED emphasized its unique position as the only Korean company to have obtained both Japan PMDA and China NMPA Class III medical device approvals, a significant achievement that strengthens the company’s competitiveness in highly regulated international markets.
These regulatory milestones provide a strong foundation for expansion into the Middle East, Europe, and other global healthcare markets.
Statement from CEO Edward BG Shin
Commenting on the company’s participation, Edward BG Shin, CEO of REV-MED, stated:
“Being recognized by Forbes Korea for innovative technology validates our commitment to delivering predictable and reliable regenerative solutions. Through the synergy of NovaStem and Calm Laser, we aim to establish new standards not only across the MENA region but throughout the global regenerative medicine market.”
REV-MED plans to continue expanding its international presence through innovation, scientific collaboration, and advanced regenerative medicine technologies.
Source: Medisobizanews (Medi Consumer News)
NovaStem (NOVASTEM), recognized by Forbes Korea as one of Korea’s innovative technologies, demonstrates its technological excellence on the global stage.
Calm Laser, a new regenerative laser platform, unveiled for the first time, highlighting synergistic applications with autologous cell concentrates.
As the only Korean company holding both Japan PMDA and China NMPA Class III Medical Device approvals, REV-MED continues to set new global standards in regenerative medicine.
Global regenerative medicine company REV-MED Co., Ltd. (CEO: Edward BG Shin) participated in WHX Dubai 2026 (formerly Arab Health), the largest healthcare exhibition in the Middle East and North Africa (MENA) region, held from February 9–12, 2026 at the Dubai Exhibition Centre, showcasing Korea’s advanced regenerative medicine technologies to an international audience.
At the exhibition, REV-MED prominently featured its flagship platform, NovaStem (NOVASTEM), which was recently recognized by Forbes Korea as an innovative technology product. Built on proprietary autologous biologics separation and concentration technology, NovaStem has attracted significant attention from healthcare professionals worldwide for transforming the uncertainty of regenerative therapies into a more standardized and reliable process.
Global buyers visiting the REV-MED booth expressed strong interest in NovaStem’s precise cell concentration technology and user-friendly workflow. The platform’s technological sophistication, validated through industry recognition, has served as a key driver in discussions with potential international partners.
Introducing Calm Laser: A New Regenerative Medicine Platform
REV-MED also unveiled its latest innovation, Calm Laser, a micro-pulse ND:YAG laser system, presenting a new direction for regenerative medicine applications.
Calm Laser is designed to deliver energy deep into the dermis while minimizing epidermal damage, helping stimulate dormant cellular activity and supporting tissue regeneration.
The company highlighted a next-generation treatment concept that combines:
This integrated regenerative approach received positive feedback from healthcare professionals and industry stakeholders attending the exhibition.
Comprehensive Product Portfolio
In addition to NovaStem and Calm Laser, REV-MED showcased several key technologies, including:
Together, these products demonstrate REV-MED’s commitment to providing a comprehensive regenerative and aesthetic technology portfolio.
Global Regulatory Leadership
REV-MED emphasized its unique position as the only Korean company to have obtained both Japan PMDA and China NMPA Class III medical device approvals, a significant achievement that strengthens the company’s competitiveness in highly regulated international markets.
These regulatory milestones provide a strong foundation for expansion into the Middle East, Europe, and other global healthcare markets.
Statement from CEO Edward BG Shin
Commenting on the company’s participation, Edward BG Shin, CEO of REV-MED, stated:
“Being recognized by Forbes Korea for innovative technology validates our commitment to delivering predictable and reliable regenerative solutions. Through the synergy of NovaStem and Calm Laser, we aim to establish new standards not only across the MENA region but throughout the global regenerative medicine market.”
REV-MED plans to continue expanding its international presence through innovation, scientific collaboration, and advanced regenerative medicine technologies.
Source: Medisobizanews (Medi Consumer News)